OncoMatch

OncoMatch/Clinical Trials/NCT07332000

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Is NCT07332000 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies aglatimagene besadenovec + valacyclovir for prostate cancer patients treated by radiotherapy.

Phase 2RecruitingCandel Therapeutics, Inc.NCT07332000Data as of May 2026

Treatment: aglatimagene besadenovec + valacyclovir — Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Required: Stage INTERMEDIATE-RISK (NCCN CRITERIA) (NCCN)

Excluded: Stage REGIONAL LYMPH NODE INVOLVEMENT, DISTANT METASTASES

Participants meeting National Comprehensive Cancer Network (NCCN) intermediate-risk criteria; Regional lymph node involvement or distant metastases [excluded]

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Cannot have received: any prior treatment for prostate cancer

Exception: transurethral resection of the prostate (TURP)

Prior treatment for prostate cancer except transurethral resection of the prostate (TURP). If prior TURP, participants must be deemed able to receive multiple intra-prostatic injections by the Investigator.

Cannot have received: orchiectomy

Participants who had or plan to have orchiectomy as the form of hormonal ablation

Lab requirements

Blood counts

White blood cells > 3000/mm3; Platelets >100,000/mm3

Kidney function

Serum creatinine < 2 mg/dL; Calculated creatinine clearance > 30 mL/min

Liver function

AST < 3 x upper limit of normal

The following laboratory criteria must be met (treatment group only): AST < 3 x upper limit of normal; Serum creatinine < 2 mg/dL; Calculated creatinine clearance > 30 mL/min; White blood cells > 3000/mm3; Platelets >100,000/mm3

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Academic Urology and Urogynecology of Arizona · Peoria, Arizona
  • Colorado Clinical Research · Lakewood, Colorado
  • Urology Associates · Littleton, Colorado
  • Chesapeake Urology Research Associates · Towson, Maryland
  • Sheldon Freedman, MD Ltd. · Las Vegas, Nevada

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify